Almirall, S.A. (ALM), a global biopharmaceutical company focused on medical dermatology, announced today the publication of Week 16 and Week 52 results of ADvocate1 and ADvocate2 by the New England Journal of Medicine (NEJM) and the British Journal of Dermatology (BJD), respectively. ADvocate1 and ADvocate2 are two .
LEO Pharma Announces British Journal of Dermatology Publication of Adbry™ (tralokinumab-ldrm) Pooled Safety Data in Moderate-to-Severe Atopic Dermatitis streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
WEDNESDAY, March 2, 2022 (HealthDay News) The overall risk for acne is comparable for adults with atopic dermatitis (AD) and controls, according to a study published online Feb. 26 in the Journal of the European Academy of Dermatology and Venereology. Jacob P. Thyssen, M.D., Ph.D., from the University of Copenhagen in Denmark, and colleagues […]
WEDNESDAY, March 2, 2022 (HealthDay News) The overall risk for acne is comparable for adults with atopic dermatitis (AD) and controls, according to a study published online Feb. 26
WEDNESDAY, March 2, 2022 (HealthDay News) The overall risk for acne is comparable for adults with atopic dermatitis (AD) and controls, according to a study published online Feb. 26